ISSN : 2146-3123
E-ISSN : 2146-3131

Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive Her2-negative Advanced Breast Cancer: Retrospective Multicenter Trial
Atakan Demir1, Nil Molinas Mandel2, Semra Paydas3, Gökhan Demir1, Özlem Er1, Nazım Serdal Turhal4, Sevil Bavbek2, Yeşim Eralp1, Pınar Mualla Saip5, Nilüfer Güler6, Adnan Aydıner5, Başak Oyan Uluç1, Sadettin Kılıçkap6, Necdet Üskent4, Nuri Karadurmuş7, Mehmet Ali Kaplan8, Mustafa Teoman9, Teoman Yanmaz9, Hacer Demir10, Özkan Alan11, Taner Korkmaz1, Polat Olgun12, Özlem Sönmez Uysal1, Kadri Altundağ13, Şeyda Gündüz14, Meral Günaldı15, Murat Sarı5, İsmail Beypınar10, Gül Başaran1
DOI : 10.4274/balkanmedj.galenos.2019.11.143

Introduction: The synthesis of CDK4/6 inhibitors with treatment of endocrine in start two series of treatment has been widely accepted as the standard for Esterogen (ER)-positive MBC (metastatic breast cancer) patients. In spite of, the activity of CDK4/6 inhibitors in MBC patients who had progressed despite receiving multiple lines of treatment is not well understood.
Aim:  We aimed to report on the activity and safety of a CDK4/6 inhibitor (palbociclib) for patients who had failed at least three lines of treatment for ER+/ MBC.
Study Design: Multi-center  retrospective observational cohort study
Methods: In this retrospective observational cohort study, we included 43 patients, whom were given palbociclib after at least 3 lines of systemic treatment for ER-positive/HER2-negative MBC.
Results: Overall, the median progression-free survival in our population was 7 months (25th percentile = 4, 75th percentile = 10) (Figure 1) and median overall survival was 11 months (25th percentile = 6, 75th percentile = 19). Although there were some adverse events, palbociclib was generally well tolerated, so dose reduction was needed for only 6 (14%) patients.
Conclusion: We demonstrated that the efficacy of palbociclib among heavily treated hormone receptor-positive/HER2-negative advanced BC patients was acceptable clinical benefit, and it was generally well tolerated among this population.

Keywords : Breast cancer, cdk4/6 inhibitors, palbociclib
Viewed : 130
Downloaded : 185